BMY - Bristol-Myers Squibb Company
After hours:
| Previous close | 64.56 |
| Open | 64.51 |
| Bid | 63.84 x 900 |
| Ask | 63.81 x 1400 |
| Day's range | 63.70 - 64.97 |
| 52-week range | 63.70 - 81.44 |
| Volume | |
| Avg. volume | 7,974,243 |
| Market cap | 134.076B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | 18.61 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.28 (3.57%) |
| Ex-dividend date | 06 Apr 2023 |
| 1y target est | N/A |
- Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
PRINCETON, N.J., May 26, 2023--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable...
- Business Wire
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023
PRINCETON, N.J., May 25, 2023--BMS's Breyanzi is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic....
- Business Wire
Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
PRINCETON, N.J., May 25, 2023--BMS to Present First Results at ASCO & EHA from Phase 3 COMMANDS Study of Reblozyl in First-Line Treatment...
- Business Wire
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
PRINCETON, N.J., May 25, 2023--Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program
- Business Wire
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
PRINCETON, N.J., May 22, 2023--Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
- Business Wire
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
PRINCETON, N.J., May 03, 2023--BMS Receives European Commission Approval for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
- Business Wire
Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
NEW YORK, May 02, 2023--Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
- Business Wire
U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
PRINCETON, N.J., May 01, 2023--FDA Accepts for Priority Review supplemental Biologics License Application and European Medicines Agency Validates Application for Reblozyl
- Business Wire
Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
PRINCETON, N.J., May 01, 2023--Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi in R/R FL and MCL Meet Primary Endpoint of Overall Response Rate
- Business Wire
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
NEW YORK, April 27, 2023--Bristol Myers Squibb Reports First Quarter Financial Results for 2023
- Business Wire
Bristol Myers Squibb Announces Leadership Transition Plan
NEW YORK, April 26, 2023--Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023. Christopher Boerner, PhD, EVP, Chief Commercialization Officer, has been named EVP, Chief Operating Officer, effective immediately, and will succeed Caforio as CEO on November 1, 2023. The Board also intends to appoint Boerner as a member of the Board after the Annual
- Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
PRINCETON, N.J., April 26, 2023--BMS Receives Positive CHMP Opinion Recommending Approval for CAMZYOS for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
- Business Wire
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
PRINCETON, N.J., April 26, 2023--Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
- Business Wire
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
PRINCETON, N.J., & CAMBRIDGE, Mass., April 17, 2023--Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and ....
- Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
PRINCETON, N.J., March 31, 2023--BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
- Business Wire
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial
PRINCETON, N.J., March 30, 2023--Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung...
- Business Wire
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
PRINCETON, N.J., March 28, 2023--BMS Receives European Commission Approval of Sotyktu (deucravacitinib) Once-Daily Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
- Business Wire
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
PRINCETON, N.J., March 15, 2023--Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
- Business Wire
Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023
NEW YORK, March 09, 2023--Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023
- Business Wire
Bristol Myers Squibb Announces Dividend
NEW YORK, March 03, 2023--Bristol Myers Squibb Announces Dividend
- Business Wire
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
PRINCETON, N.J., March 03, 2023--BMS Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
- Business Wire
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
PRINCETON, N.J., March 02, 2023--BMS-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
- Business Wire
Bristol Myers Squibb to Participate in Cowen’s 43rd Annual Health Care Conference
NEW YORK, February 28, 2023--Bristol Myers Squibb to Participate in Cowen’s 43rd Annual Health Care Conference
- Business Wire
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
PRINCETON, N.J., February 28, 2023--US FDA Accepts BMS's Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo.....
- Business Wire
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
PRINCETON, N.J., February 27, 2023--BMS to Present Data Supporting its Cardiovascular Portfolio at #ACC23/#WCCardio
